NuGel by Shaperon for Sepsis: Likelihood of Approval
NuGel is under clinical development by Shaperon and currently in Phase I for Sepsis. According to GlobalData, Phase I drugs…
NuGel is under clinical development by Shaperon and currently in Phase I for Sepsis. According to GlobalData, Phase I drugs for Sepsis does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the NuGel LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NuGel overview
NuGel (sodium taurodeoxycholic acid) is under development for the treatment of atopic dermatitis and sepsis. The drug is composed of sodium taurodeoxycholate. It is administered through transdermal route as gel formulation. It acts by targeting the GPCR19.
Shaperon overview
Shaperon is a biopharmaceutical development company that is engaged in research and development of pneumonia therapy and alzheimer’s disease therapy. The company is headquartered in Seoul, South Korea.
For a complete picture of NuGel’s drug-specific PTSR and LoA scores, buy the report here.
What's Your Reaction?
